Open AccessProbiotics – between offer and confirmation
Author(s) -
Loredana Piloff,
Facultatea de Medicină Sibiu
Publication year - 2016
Publication title -
romanian medical journal
Language(s) - English
Resource type - Journals
eISSN - 2069-606X
pISSN - 1220-5478
DOI - 10.37897/rmj.2016.1.15
Subject(s) - medicine , lactose intolerance , irritable bowel syndrome , diarrhea , inflammatory bowel disease , atopy , enterocolitis , atopic dermatitis , antibiotic associated diarrhea , disease , gastroenterology , intensive care medicine , antibiotics , clostridium difficile , allergy , immunology , lactose , food science , biology , microbiology and biotechnology
The significant increase (35-67%) of sales of probiotics requires an analysis of the justification for this use in relation to the evidence supported studies. EFSA (European Food Safety Authority) supports their efficiency potential, but warns that they are insufficient proven cause-effect relationship yet. Recommendation of these preparations are made for: gastroenteritis, diarrhea associated with antibiotics, lactose intolerance, atopy in children, atopic dermatitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, bacterial vaginosis, as an adjuvant in dyslipidemia, gastroduodenitis with Helicobacter pylori. According to records of current research results they are needed new data from the main regulatory agencies (FDA and EFSA) to guide treatment recommendations for probiotics.